Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity with Stereotactic Body Radiation Therapy for Central Non-Small Cell Lung Cancer
Clinical validation of protocol-specified dosimetric constraints for the proximal bronchial tree (PBT) is limited for central non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT). We sought to validate RTOG PBT constraints with a large institutional dataset.
This article provides an overview of the current state of knowledge of the clinical experience using radiation therapy in combination with immune therapy and discusses the rationale for integrating these 2 modalities in the treatment of advanced non–small cell lung cancer. Available data supports the use of radiation therapy in combination with immunotherapy to achieve improved local and systemic tumor control. Evidence from the early clinical trials has shown that using radiation therapy and immune checkpoint blockade therapies together produces a greater clinical effect than using either modality alone. To maximize...
Conclusions: SBRT results in excellent local control (LC) and acceptable survival in medically inoperable ES-NSCLC with minimal adverse effects. Charlson comorbidity index and target volume are important prognostic factors and may aid in patient selection.
AbstractIntroductionThe aim of the study was to extract anthropometric measures from CT by deep learning and to evaluate their prognostic value in patients with non-small-cell lung cancer (NSCLC).MethodsA convolutional neural network was trained to perform automatic segmentation of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and muscular body mass (MBM) from low-dose CT images in 189 patients with NSCLC who underwent pretherapy PET/CT. After a fivefold cross-validation in a subset of 35 patients, anthropometric measures extracted by deep learning were normalized to the body surface area (BSA) to contr...
CONCLUSION: Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages. PMID: 32013812 [PubMed - in process]
In this Oncology Scan, we summarize 3 recent, prospective, randomized studies that have explored the role of local consolidative therapy (LCT), and in some more specifically, stereotactic ablative radiation therapy (SABR), in the setting of oligometastatic non-small cell lung cancer and its impact on cancer outcomes and survival. The oligometastatic state generally refers to a situation with a limited number of metastases and where the possibility to extend survival may materialize from metastases-directed treatments.
Wu and colleagues1 have submitted an analysis from a large national cohort to examine overall survival differences of sublobar resection versus stereotactic body radiation therapy (SBRT) or percutaneous thermal ablation in the treatment of early stage non –small cell lung cancer (NSCLC). The authors queried the National Cancer Database (NCDB) for patients harboring clinical stage I (T1abc-T2a N0) NSCLC from 2004 to 2014 treated with either sublobar resection (wedge or segmentectomy), versus nonsurgical modalities such as SBRT or percutaneous therma l ablation.
The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosu...
The standard of care in management of patients with good performance status and unresectable stage III non-small cell lung cancer (NSCLC) therapy is concurrent chemoradiation. Newer techniques such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are replacing 3-dimensional conformal radiation (3DCRT) despite low-quality evidence of improved outcomes. We used population-based data to examine survival outcomes by radiation technique.
ConclusionsSBRT for clinically diagnosed lung cancers is efficacious in appropriately selected patients, with similar outcomes as those with a pathologic diagnosis. Thorough clinical and radiographic evaluations in a multidisciplinary setting are critical to the management of these patients.
For non-operable stage I non-small cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT) has emerged as a standard treatment option. We aimed to compare the clinical outcomes of lung SBRT between patients with versus without pathological cancer diagnosis.